JAK2 and acquired polycythemia vera: Treatment with JAK2 inhibitors can attenuate these symptoms[13]–[15], thus, there is genetic, cell based, and in vivo evidence to suggest a functional role for mutant JAK2 in the pathology of PV, and it is reasonable to predict that targeting the JAK2 protein could have therapeutic benefit in this patient population.